Drug intelligence / Profile preview

miR-363-3p mimics

Development stage
Preclinical
Modality
RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous
01

Overview

miR-363-3p mimics are synthetic double-stranded RNA molecules designed to replicate the biological activity of the endogenous microRNA miR-363-3p. In the context of non-small cell lung cancer (NSCLC), miR-363-3p acts as a tumor suppressor, and its expression is frequently downregulated in tumor tissues compared to normal adjacent tissues. These mimics function by binding to the 3' untranslated region (3'UTR) of target mRNAs, specifically Cullin 4A (CUL4A), leading to the downregulation of CUL4A mRNA and protein levels. By inhibiting CUL4A, miR-363-3p mimics can suppress cancer cell proliferation and enhance the sensitivity of NSCLC cells to chemotherapeutic agents such as gemcitabine, thereby potentially overcoming chemotherapy resistance.

Other names
microRNA-363-3p mimicsmicroRNA363-3p mimicsmicroRNA 363-3p mimicshsa-miR-363-3p mimicshsa-miR363-3p mimicshsa-miR 363-3p mimics
02

Targets

Proliferating cell nuclear antigen (PCNA) messenger RNA 3' untranslated regionAURKA (Aurora kinase A)Cullin 4A messenger RNA 3' untranslated region (CUL4A mRNA 3'UTR)SOX4 (SRY-box transcription factor 4)IFITM1

Beyond the preview

Go deeper on miR-363-3p mimics.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-363-3p mimics.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call